Evidence map›Paper›PMID 32251632›Full record

ArticleLife sciences2020

High ErbB3 activating activity in human blood is not due to circulating neuregulin-1 beta.

Emmanuel Boateng, Joanne T deKay, Sarah M Peterson, Jacob Boles, Nathan Pinnette, Mary Sorcher Weatherbee, Michael P Robich, Douglas B Sawyer, Sergey Ryzhov

Open access · greenAbstract read
In one paragraph

Article in Life sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 1 country.

Emmanuel BoatengThe Ohio State University College of Medicine, Columbus, OH, United States of America.
Joanne T deKayJohns Hopkins University, Baltimore, MD, United States of America.
Sarah M PetersonMaine Medical Center Research Institute, Scarborough, ME, United States of America; IDEXX Laboratories, Westbrook, ME, United States of America.
Jacob BolesMaine Medical Center Research Institute, Scarborough, ME, United States of America.
Nathan PinnetteUniversity of Rochester, Rochester, NY, United States of America.
Mary Sorcher WeatherbeeDepartment of Biology, University of Southern Maine, Portland, ME, United States of America; Department of Biology, University of Nevada, Reno, NV, United States of America.
Michael P RobichMaine Medical Center Research Institute, Scarborough, ME, United States of America; Maine Medical Center, Cardiovascular Institute, Portland, ME, United States of America.
Douglas B SawyerMaine Medical Center Research Institute, Scarborough, ME, United States of America; Maine Medical Center, Cardiovascular Institute, Portland, ME, United States of America.
Sergey RyzhovMaine Medical Center Research Institute, Scarborough, ME, United States of America. Electronic address: sryzhov@mmc.org.
Maine Medical Center · USJohns Hopkins University · USMaine Medical Center Research Institute · USThe Ohio State University · USUniversity of Rochester · USUniversity of Southern Maine · US

Funding

Understanding Factors Influencing COVID-19 Testing and Vaccination in Immigrant Low-income and Homeless Populations and Testing Targeted InterventionsU54GM115516 · NIGMS · MAINEHEALTH · PI CLIFFORD JAMES ROSEN · 2017 to 2026
$51.6M
Optimizing Cardiovascular Stem Cells for Cardiac Repair and RegenerationU01HL100398 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI HATZOPOULOS, ANTONIS · 2009 to 2015
$8.0M
Progenitor Cell Analysis CoreP30GM106391 · NIGMS · MAINEHEALTH · PI SATHYANARAYANA, PRADEEP · 2013 to 2017
$5.7M
Neuregulin signaling in myeloid cellsR01HL136560 · NHLBI · MAINEHEALTH · PI Sergey Ryzhov · 2017 to 2026
$3.3M
Molecular determinants of the fate of human heart mesenchymal progenitor cellsR01HL139887 · NHLBI · MAINEHEALTH · PI SAWYER, DOUGLAS B, VARY, CALVIN PARDEE HULL · 2019 to 2022
$2.0M
NHLBI NIH HHS R01 HL136560NHLBI NIH HHS R01 HL139887NHLBI NIH HHS U01 HL100398NIGMS NIH HHS P30 GM106391NIGMS NIH HHS U54 GM115516
6 · The paper itself

Abstract

Neuregulin-1β (NRG-1) is a membrane-bound or secreted growth and differentiation factor that mediates its action by binding to ErbB receptors. Circulating levels of NRG-1 are characterized by large inter-individual variability with the range of absolute values covering two orders of magnitude, from hundreds to tens of thousands of picograms per milliliter of blood. NRG-1 signaling via ErbB receptors contributes to the cell survival and downregulation of the inflammatory response. A higher level of circulating NRG-1 may indicate increased shedding of membrane-bound NRG-1, which in turn can contribute to better protection against cardiovascular stress or injury. However, it is unknown whether circulating NRG-1 can induce activation of ErbB receptors. In the current study, we performed an analysis of circulating NRG-1 functional activity using a cell-based ELISA measuring phosphorylation of ErbB3 induced by blood plasma obtained from healthy donors. We found high levels of ErbB3 activating activity in human plasma. No correlations were found between the levels of circulating NRG-1 and plasma ErbB3 activating activity. To determine the direct effect of circulating NRG-1, we incubated plasma with neutralizing antibody, which prevented the stimulatory effect of recombinant NRG-1 on activation of ErbB3. No effect of the neutralizing antibody was found on plasma-induced phosphorylation of ErbB3. We also found that a significant portion of circulating NRG-1 is comprised of full-length NRG-1 associated with large extracellular vesicles. Our results demonstrate that circulating NRG-1 does not contribute to plasma-induced ErbB3 activating activity and emphasizes the importance of functional testing of NRG-1 proteins in biological samples.

Indexed as

AdultAgedAntibodies, NeutralizingCell SurvivalDown-RegulationEnzyme-Linked Immunosorbent AssayFemaleHumansMaleMiddle AgedNeuregulin-1PhosphorylationReceptor, ErbB-3Antibodies, NeutralizingcimaglerminERBB3 protein, humanNeuregulin-1Receptor, ErbB-3CirculationErbB receptorsExtracellular vesiclesNeuregulin-1NRG-1 neutralizing antibody

Identifiers

PMID32251632
PMCPMC7233313
OpenAlexW3014591641

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.